TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04266366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face Rehabilitation program
Description: In each hospital, two trained therapists will carry out a face-to-face rehabilitation program consisting of electroanalgesia and an exercise program that follows the Mckenzie method. The physiotherapists place the electrodes in the patients, for this they use 5x9 cm electrodes, which they place at the bilateral paravertebral level, in the patients who present with radicular pain, the electrodes will be placed in the path of the affected nerve. The duration will be sufficient to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal periarticular components of the spine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine program
Description: It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
Study: NCT04131699

Intervention type: DEVICE
Intervention: Cardiotronic ICON continuous non-invasive cardiac output monitor.
Description: cardiac index, cardiac output \& stroke volume measured and recorded with every change in intrathoracic pressure.
Study: NCT04836234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum
Description: Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum 65g 40 pieces
Study: NCT01693159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECA
Description: In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard topical treatment of the institution, e.g. Lotio
Description: Standard treatment of the institution to treat painful cetuximab-induced rhagades
Study: NCT02127983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early intervention
Description: Training non-paid informal healthcare providers (such as store-keepers) in TB and HIV disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness.~Front line public health personnel and community leaders were sensitised to support the intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed intervention
Description: Delayed intervention arm, engaging informal providers Received the intervention after one year
Study: NCT02270463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp-erzs
Description: Tagraxofusp-Erzs administered by IV infusion at doses of 7, 9, and 12 µg/kg/day
Study: NCT01638533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT06684067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: Participants will receive online educational material, hospital site navigation guidance and direct contact with the patient navigator, in addition to standard instructions on the colonoscopy procedure.
Study: NCT04102176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stopping nucleos(t)ide therapy
Description: patients taking nucleoside(t)ide therapy will stop treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continue nucleos(t)ide analogue
Description: Continue nucleos(t)ide analogue
Study: NCT00411242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02196688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fruquintinib
Description: fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
Study: NCT03636204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AL001
Description: Active dose of AL001

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution administered as a single infusion as palcebo.
Study: NCT01355016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDT-637
Description: Inhaled doses of MDT-637 over a 24 hour period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MDT-637
Description: Inhaled doses of MDT-637 over a 24 hour period
Study: NCT04674917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
Description: Group A which includes the acute group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 ) Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decompression + Hot pack , TENS , Mobilization , Exercise Therapy
Description: Group B which includes the chronic group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression.

Intervention type: OTHER
Group type: OTHER
Intervention: Hot pack , TENS, Mobilization, Exercise therapy
Description: Group C which is our control group to compare it with the groups A and B to study the effects of decompression on lumbar radiculopathy The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine It is kept in mind that in this group we will not apply the decompression along with the above treatments.
Study: NCT02251106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar corset (Quickdraw, Aspen Medical Products)
Description: The corset (a.k.a. brace) is made of webbing and elastic. It is wrapped around the trunk and tightened with Velcro and a series of cords (like tying shoes).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar corset (Quickdraw, Aspen Medical Products)
Description: The corset (a.k.a. brace) is made of webbing and elastic. It is wrapped around the trunk and tightened with Velcro and a series of cords (like tying shoes).
Study: NCT04875728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Undergo standard of care surgical resection
Study: NCT01638533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV
Study: NCT04875728

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo standard of care surgical resection
Study: NCT00647387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)
Description: Device
Study: NCT04259658

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Patients with cutaneous metastases will be treated with calcium electroporation.
Study: NCT00685724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.
Study: NCT01516606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin, oral, high dose
Description: 2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
Study: NCT03386305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EnvarsusXR
Description: Patients randomized to study drug will be converted to EnvarsusXR once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Patients continue to take Tacrolimus BID, as a part of routine care.
Study: NCT03273283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
Study: NCT02203045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Study: NCT04809298

Intervention type: DEVICE
Group type: OTHER
Intervention: Free-hand therapeutic CT-guided punction for lumbar pain
Description: Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puncture Cube
Description: Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
Study: NCT02661490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride (saline)
Description: norovirus bivalent placebo-matching vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride (saline)
Description: norovirus bivalent placebo-matching vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride (saline)
Description: norovirus bivalent placebo-matching vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
Study: NCT02600897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
Study: NCT02140450

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Artificial tears, 2 drops, 1-2 hours before intravitreal injection
Study: NCT05329636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplant (FMT)
Description: FMT through capsules- patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen capsules on two consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen placebo-capsules on two consecutive days.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Auto Fecal Microbial Transplant (FMT) via enema
Description: 3.FMT through enema- patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema. Enemas will be administered with the assistance of the study nurse. Patients will be asked to hold the enema content for at least 15 minutes.
Study: NCT01800565

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of LH in first-voided urine
Description: participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.

Intervention type: OTHER
Group type: OTHER
Intervention: collection of first-voided urine sample for LH level
Description: participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
Study: NCT01711021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-Amphetamine Transdermal Patch
Description: The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
Study: NCT01867242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes
Description: Smoke their usual brand of cigarettes and follow their normal patterns of use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes
Description: Smoke their usual brand of cigarettes and follow their normal patterns of use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snus
Description: Winterchill or Robust flavors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snus
Description: Winterchill or Robust flavors
Study: NCT01075763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] administered subcutaneously (sc)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
Study: NCT01584661

Intervention type: BEHAVIORAL
Intervention: Dietary recommendations
Study: NCT02129023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xbox 360
Description: For each participant in the experimental arm, two Xbox 360 exercise items were randomly selected from the nine items, which are related to user health. Each participant takes the two exercise items in turn.
Study: NCT00678392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: axitinib will be given at a starting dose of 5 mg twice daily \[BID\] with continuous dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: sorafenib will be given at a dose of 400 mg twice daily \[BID\] with continuous dosing
Study: NCT01717898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10/mg po daily. Prednisone can be modified at the investigator's discretion, but should not be discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: 1000 mg, po. Abiraterone Acetate is supplied in 250 mg white tablets, four tablets are to be taken with a full glass of water on an empty stomach once daily.
Study: NCT02371798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine
Description: IV administration of 0.2 mmol/kg of Gd-DTPA
Study: NCT03175120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide
Description: Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
Study: NCT04076358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tab-CBI
Description: Participants receive a tablet preloaded with Tab-CBI application and an accelerometer.
Study: NCT02180308

Intervention type: DEVICE
Intervention: PET/MRI
Description: Simultaneous PET/MRI (3T system)
Study: NCT02419677

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Description: The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Study: NCT00685724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: In CBT, clients learn to modify their thoughts as well as their behaviors by increasing awareness of the relationship between thoughts, emotions, and actions.
Study: NCT02507375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered as oral tablets.
Study: NCT01337466

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [124I]FIAU
Description: This is a single dose study of 2 mCi \[124I\]FIAU in healthy volunteers or subjects with prosthetic joint infection of the knee or hip who will undergo serial PET-CT scanning.
Study: NCT05033262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Our Memory Care Wishes
Description: Our Memory Care Wishes is a web-based advance care planning platform designed for persons living with dementia in nursing homes to discuss and document healthcare and daily life preferences with the help of shared decision-makers. Penn researchers meet via Zoom with PLWD and their SDMS and nursing home staff to facilitate website completion.
Study: NCT02600897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
Study: NCT02126267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
Study: NCT02600897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
Study: NCT05242913

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Potato Starch
Description: Unmodified potato starch containing \>60% resistant starch Type 2

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Potato Starch
Description: Unmodified potato starch containing \>60% resistant starch Type 2
Study: NCT02126267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full mouth disinfection
Description: Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full mouth disinfection
Description: Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days